-
Catumaxomab, sold
under the
brand name
Removab among others, is a rat-mouse
hybrid monoclonal antibody which is used to
treat malignant ascites, a condition...
- T cell/cancer cell
interactions using label-free live cell imaging.
Catumaxomab, one of the
first trifunctional antibodies approved for
therapeutic use...
-
cells from
malignant ascites fluid were
eliminated due to
catumaxomab treatment.
Catumaxomab, was the
first to be
approved for
clinical use (in 2009 for...
- Catapres-TTS
Catarase Cathflo Activase cathine (INN)
cathinone (INN)
Catiolanze catramilast (USAN, INN)
catridecacog (INN)
catumaxomab (INN)
Caverject Cayston...
-
antibodies have
arrived in the clinic. In 2009, the
bispecific antibody catumaxomab was
approved in the
European Union and was
later withdrawn for commercial...
-
Ramucirumab L01FX01
Edrecolomab L01FX02
Gemtuzumab ozogamicin L01FX03
Catumaxomab L01FX04
Ipilimumab L01FX05
Brentuximab vedotin L01FX06
Dinutuximab beta...
- oncology/immune
indications Carotuximab mab
chimeric endoglin angiosarcoma Catumaxomab Removab 3funct rat/mouse
hybrid EpCAM, CD3 Y
ovarian cancer, malignant...
-
Trastuzumab emtansine Trastuzumab deruxtecan)
Others for
solid tumors EpCAM (
Catumaxomab Edrecolomab) VEGF-A (Bevacizumab) Leukemia/lymphoma lymphoid: CD3 (Glofitamab...
- Lor****, F.; Ott, K.; Weitz, J.; Jäger, D. (2008). "The
evolving role of
catumaxomab in
gastric cancer".
Expert Opinion on
Biological Therapy. 8 (9): 1407–15...
-
Trastuzumab emtansine Trastuzumab deruxtecan)
Others for
solid tumors EpCAM (
Catumaxomab Edrecolomab) VEGF-A (Bevacizumab) Leukemia/lymphoma lymphoid: CD3 (Glofitamab...
